found that pulmonary endothelial specific deletion of HIF2a, achieved using murine cre-loxp technologies (L1 or alk1-cre), offers protection against hypoxia-induced PAH. The rise in pulmonary artery pressure (PAP) normally observed following chronic hypoxic challenge was absent in mice with pulmonary endothelial HIF2a deletion. The right ventricular systolic pressure of L1cre-HIF2a mice post hypoxic challenge (26.17 ±1.67 mmHg, n=7) was not significantly different from untreated WT mice (22.48±1.19 mmHg, n=9) and much lower than the hypertensive values seen in WT littermate controls (41.91±1.88 mmHg, n=12, p<0.0001) and L1cre-HIF1a mice (36.25±2.37 mmHg, n=7, p<0.005). Only minimal remodelling was observed in lung sections from L1cre-HIF2a mice reflecting the normal physiological PAPs following chronic hypoxia. We next questioned whether deletion of lung endothelial HIF2a would be sufficient to reduce downstream arginase-1 and À2 gene expression and in turn influence plasma nitrite/nitrate (NO (X) ) concentrations, which would be indicative of changes in nitric oxide homeostasis. The expression of both arginase-1 and À2 were significantly reduced in hypoxia-conditioned whole lung samples from L1cre-HIF2a mice relative to WT littermate controls. Plasma NO (X) concentrations were also significantly elevated in the HIF2a mutant mice when compared to plasma from WT control mice. These observations fit a model whereby reduced arginase-1/2 expression leads to increased availability of l-arginine, and in turn increased NO synthesis via NO synthases. These data offer new insights into the role of pulmonary endothelial HIF2a in causing PAH, and offer new therapeutic opportunities for the treatment of this condition. Introduction Evidence has implicated neutrophil elastase (NE), a proteolytic enzyme, as a key driver of the pulmonary vascular remodelling that underlies pulmonary arterial hypertension (PAH). Moreover, studies using animal models and explanted human lung tissue have demonstrated that inhibition of NE attenuates pulmonary hypertension. However, there has been little investigation into neutrophil function in PAH patients even though their azurophilic granules are the main physiological reservoir of NE. We investigated neutrophil phenotypes in patients with PAH versus healthy controls, with a focus on neutrophil degranulation. Methods Neutrophils were isolated from venous blood of PAH patients and healthy controls (HC) and treated with LPS; viability was assessed at 20 hours by morphology. Cell surface receptor expression was determined by flow cytometry. To evaluate degranulation, neutrophils were treated with priming agents, platelet activating factor (PAF, 1 mM) or tumour necrosis factor-a (TNF, 20 ng/ml), and subsequently stimulated with N-formylmethionyl-leucyl-phenylalanine (fMLP; 100 nM). NE release was measured by ELISA and released NE activity and myeloperoxidase (MPO) activity were determined by fluorogenic (Enzchek) and colorimetric (o-dianisidine oxidation) assays respectively. Results Neutrophil apoptosis 20 hours following stimulation with LPS was significantly lower in PAH (25.4%+/-2.2, n=12) versus HC samples (44.9%+/-4.7, n=9), p<0.001. There were no differences in TLR2 or TLR4 expression between PAH and HC neutrophils. PAH neutrophils released greater amounts of NE following stimulation (e.g., TNF-a priming: PAH 675.2 ng/ml+/-77 vs. HC 277 ng/ml +/À18.4, p<0.0001) but there was no increase in NE activity in the same supernatants, nor any difference in released MPO activity compared to healthy controls. Conclusions Our Results indicate that neutrophil phenotype is altered in PAH, with a prolonged lifespan in response to a pro-inflammatory stimulus and increased release of NE. However, we did not detect a corresponding increase in NE activity, suggesting a concomitant increase in NE inhibitor release from PAH neutrophils. The potential role of this altered neutrophil phenotype in vascular remodelling requires further investigation.
found that pulmonary endothelial specific deletion of HIF2a, achieved using murine cre-loxp technologies (L1 or alk1-cre), offers protection against hypoxia-induced PAH. The rise in pulmonary artery pressure (PAP) normally observed following chronic hypoxic challenge was absent in mice with pulmonary endothelial HIF2a deletion. The right ventricular systolic pressure of L1cre-HIF2a mice post hypoxic challenge (26.17 ±1.67 mmHg, n=7) was not significantly different from untreated WT mice (22.48±1.19 mmHg, n=9) and much lower than the hypertensive values seen in WT littermate controls (41.91±1.88 mmHg, n=12, p<0.0001) and L1cre-HIF1a mice (36.25±2.37 mmHg, n=7, p<0.005). Only minimal remodelling was observed in lung sections from L1cre-HIF2a mice reflecting the normal physiological PAPs following chronic hypoxia. We next questioned whether deletion of lung endothelial HIF2a would be sufficient to reduce downstream arginase-1 and À2 gene expression and in turn influence plasma nitrite/nitrate (NO (X) ) concentrations, which would be indicative of changes in nitric oxide homeostasis. The expression of both arginase-1 and À2 were significantly reduced in hypoxia-conditioned whole lung samples from L1cre-HIF2a mice relative to WT littermate controls. Plasma NO (X) concentrations were also significantly elevated in the HIF2a mutant mice when compared to plasma from WT control mice. These observations fit a model whereby reduced arginase-1/2 expression leads to increased availability of l-arginine, and in turn increased NO synthesis via NO synthases. These data offer new insights into the role of pulmonary endothelial HIF2a in causing PAH, and offer new therapeutic opportunities for the treatment of this condition. Introduction Evidence has implicated neutrophil elastase (NE), a proteolytic enzyme, as a key driver of the pulmonary vascular remodelling that underlies pulmonary arterial hypertension (PAH). Moreover, studies using animal models and explanted human lung tissue have demonstrated that inhibition of NE attenuates pulmonary hypertension. However, there has been little investigation into neutrophil function in PAH patients even though their azurophilic granules are the main physiological reservoir of NE. We investigated neutrophil phenotypes in patients with PAH versus healthy controls, with a focus on neutrophil degranulation. Methods Neutrophils were isolated from venous blood of PAH patients and healthy controls (HC) and treated with LPS; viability was assessed at 20 hours by morphology. Cell surface receptor expression was determined by flow cytometry. To evaluate degranulation, neutrophils were treated with priming agents, platelet activating factor (PAF, 1 mM) or tumour necrosis factor-a (TNF, 20 ng/ml), and subsequently stimulated with N-formylmethionyl-leucyl-phenylalanine (fMLP; 100 nM). NE release was measured by ELISA and released NE activity and myeloperoxidase (MPO) activity were determined by fluorogenic (Enzchek) and colorimetric (o-dianisidine oxidation) assays respectively. Introduction Pulmonary arterial hypertension (PAH) is characterised by vascular remodelling of pulmonary arterioles. Disrupted iron homeostasis including subclinical haemolysis are implicated in PAH, although exact mechanisms remain unknown. Interactions linked to altered iron handling consequent to release of mediators by human pulmonary artery endothelial cells (hPAECS) and/or human pulmonary artery smooth muscle cells (hPASMCs) may be important in this regard. Objectives This study explored proliferative and migratory responses in hPASMCs linked to the primary exposure of hPAECs to indices of dysregulated iron homeostasis i.e., hepcidin or haemoglobin. Methods hPAECs were challenged with haemoglobin (10 uM) or hepcidin (100-1000 ng/mL). Proliferation and migration of hPASMCs were analysed using xCELLigence RTCA instrument by measuring the changes in cell index/impedance. Results Novel findings demonstrate that media conditioned with hepcidin for 48 hour from hPAECs increased proliferation of hPASMCs by 24% (95% CI 0.256-47.9, p<0.05) after 48 hour of treatment. Additionally, 24 hour conditioned media from both hepcidin and haemoglobin treated hPAECs caused 3.27 and 2.28 fold increases in migration respectively in hPASMCs. Conclusion These findings highlight a direct role for variant iron homeostasis in hPAECs which is linked to subsequent functional responses in hPASMCs of importance to vascular remodelling. These studies may provide novel insights regarding mechanisms for haemoglobin and hepcidin driven proliferative and migratory responses of relevance to PAH.
Introduction COPD is thought to result largely from neutrophilic inflammation. Relatively little focus has been given to the endothelium, through which neutrophils transmigrate to reach the lung, despite observation of abnormal amounts of endothelial tissue in COPD which behaves in a dysfunctional manner. 1 We sought to determine if coding (mRNA) and noncoding (miRNA) alterations in pulmonary endothelium exist in COPD, and if so what their effect is on endothelial function. Methods Patients with and without COPD undergoing thoracic surgery were recruited (n=52); power calculations indicated that 10 in each group were required to detect differences in miRNA between health and COPD. Human Pulmonary Endothelial Cells (HPECs) were isolated from lung tissue by positive selection using Ulex europaeus lectin-coated magnetic beads and extracted RNA used for miRNA and mRNA microarrays, as well as confirmatory qPCR. Significance Analysis of Microarrays (SAM) was used to perform differential miRNA or mRNA analysis; ingenuity pathway analysis (IPA) was also carried out to guide functional work. The miRNA which differed most between health and COPD was transfected into endothelial cells and a range of cellular functions were assessed, including matrigel and spheroid assays. Results 2071 genes and 43 miRNAs were significantly upregulated in COPD. 6 mRNAs and 8 miRNAs were appropriate for further validation. 4 targets were validated by qPCR, of which miR-181b-3p exhibited the most significant differential expression and was chosen for functional validation. IPA suggested that cell growth/proliferation, eicosanoid signalling and TGFB (transforming growth factor beta) driven pathways were the most relevant areas for further study. There was significantly reduced tube formation (figure 1) and endothelial sprouting in Human umbilical vein endothelial cells (HUVECs) transfected with miR-181b-3p, consistent with an effect on angiogenesis.
Abstract S113 Figure 1 An example of image from a matrigel experiment. A: HUVECs transfected with miR-181b-3p mimic. B: HUVECs transfected with negative siRNA. There is reduced tube formation seen in HUVECs transfected with the mimic.
Conclusions Upregulation of miR-181b-3p reduces tube formation and sprouting by endothelial cells. This might be significant in the development of emphysema as lung vasculature is important in the structural maintenance of alveoli.
2 Correcting miR-181b-3p expression levels could be a route for treating emphysema by promoting support of alveolar structure and regeneration.
